Novogenia AG, an international healthcare company specializing in human genetics and personalized health products, has released its issuer report for the first half of 2026. The report reveals a 7% decline in consolidated revenue to EUR 25.7 million, primarily due to lower volumes in the pharmaceutical and medical device trading segment caused by regulatory changes. However, the core business areas of DNA analysis and personalized products achieved positive revenue growth compared to the same period last year, signaling underlying strength in the company's primary focus.
CEO Dr. Daniel Wallerstorfer acknowledged that the financial performance did not meet expectations in all areas, but highlighted the positive year-on-year development of the core business and a significant reduction in the cost base. The company achieved cost savings in materials, personnel, and other operating expenses, leading to an improvement in operating profit of approximately EUR 2.7 million. Nevertheless, due to a decline in other operating income that had been boosted by one-time effects in the prior-year period, EBIT only improved by 4.1% to EUR -4.7 million. Consolidated net income was -EUR 2.1 million, compared to a positive EUR 2.0 million in the previous year, which had benefited from a significantly higher financial result.
Despite the mixed financial results, Novogenia made substantial strategic progress in the first half of 2026. The company expanded its collaboration with 10X Health Systems, advanced preparations for market launch in the Middle East with G42 in Abu Dhabi, and launched the enhanced Methylation Test MGT Plus in the U.S. market. It also introduced the Multi-Cancer Check and established a new software platform for its NovoDaily product line. Construction of a new company site in Hallwang near Salzburg commenced, with completion planned for early 2028. The renaming from Darwin AG to Novogenia AG was implemented in July 2026, consolidating the brand identity and streamlining communication with customers and investors.
Novogenia remains in a solid financial position with EUR 39.8 million in cash and cash equivalents as of June 30, 2026, down from EUR 71.9 million the previous year. The company will engage with investors and industry stakeholders at several upcoming conferences, including the 5th Zurich Investor Day, the Abu Dhabi Future Health Summit, the ODDO BHF Autumn Round Table, and the Deutsches Eigenkapitalforum. These events underscore Novogenia's commitment to strengthening its international presence and advancing its strategic partnerships.
The H1 2026 report highlights both challenges and opportunities for Novogenia. While regulatory changes and platform algorithm shifts have impacted sales channels, the company's core DNA analysis and personalized health products are growing, and cost reduction efforts are yielding results. The strategic initiatives, including product launches and international expansion, lay the foundation for future growth in the personalized prevention and healthcare market. As Novogenia continues to navigate a dynamic environment, its focus on innovation and partnerships will be critical to realizing its ambitious growth plans. For more information, visit https://novogenia.com/novogenia-ag. The original release is available on www.newmediawire.com.
